Upadacitinib and abrocitinib are the newest systemic immunosuppressants for the treatment of moderate to severe atopic dermatitis in patients 12 years of age or older whose disease is not adequately controlled with other systemic medications, including biologic agents, or when use of those therapies is not advisable.